Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats

[1]  A. Newman,et al.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[2]  Ji-Kyung Choi,et al.  In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias , 2007, Neurobiology of Disease.

[3]  C. Goetz,et al.  Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.

[4]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[5]  W. Danysz,et al.  Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.

[6]  N. Hermanowicz.  Drug therapy for Parkinson's disease. , 2007, Seminars in neurology.

[7]  F. Fadda,et al.  Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats , 2006, Journal of neurochemistry.

[8]  Robert H Mach,et al.  Synthesis and characterization of selective dopamine D2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[9]  J. Brotchie.  Nondopaminergic mechanisms in levodopa‐induced dyskinesia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[10]  K. Fouad,et al.  The unilateral 6‐OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis , 2005, The European journal of neuroscience.

[11]  G. Fisone,et al.  Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia , 2005, Experimental Neurology.

[12]  E. Bézard,et al.  Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. , 2005, Parkinsonism & related disorders.

[13]  W. Clarke.  What's for Lunch at the Conformational Cafeteria? , 2005, Molecular Pharmacology.

[14]  T. Chase,et al.  Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates , 2005, Experimental Neurology.

[15]  Robert H Mach,et al.  Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.

[16]  S. Senogles,et al.  D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway , 2004, Neuroscience Letters.

[17]  E. Bézard,et al.  Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  R. Mailman,et al.  Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. , 2004, Molecular pharmacology.

[19]  E. Kuzhikandathil,et al.  Identification and characterization of novel properties of the human D3 dopamine receptor , 2004, Molecular and Cellular Neuroscience.

[20]  S. Senogles.  D2s dopamine receptor mediates phospholipase D and antiproliferation , 2003, Molecular and Cellular Endocrinology.

[21]  Thomas Boraud,et al.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.

[22]  M. Cenci,et al.  Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia , 2003, Journal of neurochemistry.

[23]  R. Mach,et al.  Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. , 2003, Current pharmaceutical design.

[24]  T. Chase,et al.  Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models , 2002, Experimental Neurology.

[25]  Jos Prickaerts,et al.  Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.

[26]  Terry Kenakin,et al.  Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.

[27]  N. Wierup,et al.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.

[28]  T. Chase,et al.  Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models , 2001, Neurology.

[29]  Erwan Bezard,et al.  Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.

[30]  R. Mach,et al.  Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors , 2000, Synapse.

[31]  S. Senogles.  The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine. , 2000, Molecular pharmacology.

[32]  E. Kuzhikandathil,et al.  Dominant-Negative Mutants Identify a Role for Girk Channels in D3 Dopamine Receptor-Mediated Regulation of Spontaneous Secretory Activity , 2000, The Journal of general physiology.

[33]  P. Sokoloff,et al.  Involvement of the direct striatonigral pathway in levodopa‐induced sensitization in 6‐hydroxydopamine‐lesioned rats , 2000, The European journal of neuroscience.

[34]  T. Schallert,et al.  CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury , 2000, Neuropharmacology.

[35]  R. A. Fuchs,et al.  Behavioral interactions produced by co-administration of 7-OH-DPAT with cocaine or apomorphine in the rat , 1999, Psychopharmacology.

[36]  Weifeng Yu,et al.  Human Dopamine D3 and D2L Receptors Couple to Inward Rectifier Potassium Channels in Mammalian Cell Lines , 1998, Molecular and Cellular Neuroscience.

[37]  R. A. Fuchs,et al.  Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference , 1998, Psychopharmacology.

[38]  P. Sokoloff,et al.  Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence 1 Published on the World Wide Web on 24 November 1997. 1 , 1998, Brain Research Reviews.

[39]  P. Sokoloff,et al.  D3 dopamine receptor mRNA is widely expressed in the human brain , 1998, Brain Research.

[40]  J. Barrio,et al.  Effects of Large Neutral Amino Acid Concentrations on 6-[F-18]Fluoro-L-DOPA Kinetics , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  M. Caron,et al.  Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. , 1997, Molecular pharmacology.

[42]  K. Neve,et al.  Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. , 1997, Molecular pharmacology.

[43]  P. Sokoloff,et al.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Sokoloff,et al.  Two Intracellular Signaling Pathways for the Dopamine D3 Receptor: Opposite and Synergistic Interactions with Cyclic AMP , 1997, Journal of neurochemistry.

[45]  H. V. Van Tol,et al.  Modulation of Intracellular Cyclic AMP Levels by Different Human Dopamine D4 Receptor Variants , 1995, Journal of neurochemistry.

[46]  M. Martres,et al.  Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. , 1994, European journal of pharmacology.

[47]  P. Molinoff,et al.  Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. , 1993, The Journal of pharmacology and experimental therapeutics.

[48]  Bruno Giros,et al.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA , 1991, Brain Research.

[49]  J. G. Nutt,et al.  Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease , 1989, Neurology.

[50]  J. Pincus,et al.  Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. , 1987, Archives of neurology.

[51]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[52]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[53]  J. Perkins,et al.  Regulation of adenosine 3':5'-monophosphate content of human astrocytoma cells: desensitization to catecholamines and prostaglandins. , 1976, Journal of cyclic nucleotide research.

[54]  C. Londos,et al.  A highly sensitive adenylate cyclase assay. , 1974, Analytical biochemistry.

[55]  J. Daly,et al.  A RADIOISOTOPIC METHOD FOR MEASURING THE FORMATION OF ADENOSINE 3′,5′‐CYCLIC MONOPHOSPHATE IN INCUBATED SLICES OF BRAIN , 1969, Journal of neurochemistry.

[56]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.

[57]  A. Carlsson,et al.  Rat brain concentration of administered amino acids: Dependence on time of day for administration , 2005, Journal of Neural Transmission.

[58]  M. Lundblad,et al.  Chapte B7 - Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease , 2005 .

[59]  T. Schallert,et al.  Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism , 2000 .

[60]  P. Sokoloff,et al.  D1/D3 receptor relationships in brain coexpression, coactivation, and coregulation. , 1998, Advances in pharmacology.

[61]  R. Todd,et al.  Characterization of the human dopamine D3 receptor expressed in transfected cell lines. , 1994, European journal of pharmacology.

[62]  M. E. Lajiness,et al.  Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. , 1994, Molecular pharmacology.

[63]  S. Kuno,et al.  Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[64]  U. Ungerstedt,et al.  6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. , 1976, Pharmacology & therapeutics. Part B: General & systematic pharmacology.